TMPRSS2 and prostate cancer: Since their identification in 2005 by the pioneering studies of Arul Chinnayan [5], the TMPRSS2:ETS gene fusions have been the focus of intense investigations, as well as a point of contention with regards to its role in prostate cancer as an indicator for the aggressive phenotype.